Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baloxavir Marboxil PK in Healthy Chinese Volunteers
NCT03959332Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of baloxavir marboxil in influenza (2 arms), sponsored by Roche. Primary endpoints: Maximum Plasma Concentration at 336 hours, Time to Maximum Plasma Concentration at 336 hours and 5 more. Started Jun 2019; status: completed.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03959332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959332.